Leishmania parasite plasma membrane

The Leishmania parasite plasma membrane is an essential, highly specialized lipid bilayer that contains a unique composition of sterols (notably ergosterol), phospholipids, glycolipids, and a variety of GPI-anchored glycoproteins such as lipophosphoglycan (LPG), GP63, and others[1][4][7]. Its structure enables the parasite to adapt to mammalian and insect hosts, evade the host immune system, invade cells, and survive intracellularly. The membrane hosts numerous proteins important for virulence, nutrient uptake, and immune evasion[1][7]. While not itself a discrete drug target, many of its specific components and biosynthetic pathways, including ergosterol biosynthesis, GPI anchor biosynthesis, and surface membrane proteins, are validated or proposed therapeutic targets for anti-leishmanial drugs[1][2][4][7]. The overall structure and composition of the Leishmania plasma membrane differ significantly from mammalian cells, enabling selective therapeutic targeting but also presenting challenges due to the risk of toxicity and emerging resistance mechanisms[2][6][8].

Other names

Leishmania plasma membraneLeishmania cell membrane

Disruption of membrane sterols (ergosterol binding/permeabilization — amphotericin B); Alteration of phospholipid/fluidity and induction of apoptosis (miltefosine); Inhibition of anchoring or biosynthesis of key membrane components (e.g., targeting GPI anchor biosynthesis or surface protein maturation); Inhibition of nutrient transport, signal transduction, and immune evasion